MAXHEALTH1,033.10

Max Healthcare Institute Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAPOLLOHOSPFORTISMEDANTADRREDDYCIPLASUNPHARMADIVISLABTORNTPHARMMcap ₹1.01L Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,363.21,335.01,422.91,543.01,707.51,868.31,909.72,027.62,135.52,067.52,142.92,366.2
Other Income45.546.045.334.740.833.346.936.532.945.447.840.5
Total Income1,408.61,381.01,468.21,577.61,748.31,901.61,956.72,064.12,168.42,112.92,190.72,406.7
Expenses
+ Purchases of Stock-in-Trade278.4270.7297.4330.0359.4396.9410.1453.8465.2446.5433.3521.2
+ Changes in Inventories1.4-3.4-1.8-3.4-10.2-5.1-0.7-8.6-0.3-6.16.2-7.8
+ Employee Benefit Expense235.8230.7241.8270.2283.6304.6315.6338.1338.3340.5340.3388.2
+ Finance Costs8.511.220.723.933.552.455.254.953.959.766.771.0
+ Depreciation & Amortisation57.961.070.376.984.297.5100.8104.1108.1111.3123.0131.7
+ Other Expenses460.2451.2503.9558.8624.1672.8673.1721.4757.1748.4756.7866.2
Total Expenses1,042.21,021.31,132.41,256.31,374.61,519.11,554.21,663.71,722.31,700.11,726.11,970.4
EBITDA387.4385.9381.5387.4450.5499.1511.6522.9575.2538.3606.4598.5
EBIT329.5324.9311.2310.5366.4401.6410.8418.8467.1427.1483.4466.8
Profit
PBT before Exceptional Items366.4359.7335.7321.3373.7382.5402.5400.4446.0412.8464.6436.3
+ Exceptional Items0.00.00.00.00.0-73.60.00.00.0-48.20.00.0
Pretax Income366.4359.7335.7321.3373.7308.9402.5400.4446.0364.5464.6436.3
+ Current Tax71.275.173.681.491.791.072.196.410.346.058.682.5
+ Deferred Tax18.6-4.710.63.70.2-20.911.4-4.0-55.617.663.830.9
Tax Expense89.770.384.285.091.970.183.592.5-45.363.6122.4113.4
Net Income276.7289.3251.5236.3281.8238.8319.0308.0491.3300.9342.2323.0
+ Net Income — Continuing Ops276.7289.3251.5236.3281.8238.8319.0308.0491.3300.9342.2323.0
+ Other Comprehensive Income-4.4-0.7-0.9-1.8-2.3-0.4-0.1-2.80.0-0.11.3-4.8
Total Comprehensive Income272.3288.7250.7234.5279.5238.4318.9305.2491.3300.9343.5318.2
Net Income to Common0.0289.3250.7236.3281.8238.8491.3300.9
Per Share
Basic EPS2.852.982.592.432.902.463.283.175.053.103.523.32
Diluted EPS2.842.972.582.422.882.443.263.155.023.093.503.30
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.1-2.80.0-0.11.3-4.8
+ Items NOT to be Reclassified to P&L-5.4-0.4-0.7-2.2-2.5-0.2-0.3-3.50.20.41.10.1
+ Tax on Items NOT to be Reclassified-0.1-0.70.00.30.30.1
+ Tax on Items NOT to be Reclassified — alt tag-1.10.10.1-0.4-0.2-0.0
+ Items to be Reclassified to P&L-0.0-0.1-0.10.0-0.1-0.2-0.0-0.0-0.2-0.10.5-6.5
+ Tax on Items to be Reclassified0.00.00.00.00.0-1.6
Comprehensive Income — Owners of Parent0.0288.70.0234.5279.5238.4491.3300.9
Per Share — as-filed variants
Basic EPS — Continuing Operations2.852.982.592.432.902.463.283.175.053.103.523.32
Diluted EPS — Continuing Operations2.842.972.582.422.882.443.263.155.023.093.503.30
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,083.41,067.71,127.31,216.41,358.21,476.51,500.31,582.31,670.61,627.21,703.41,852.8
Gross Margin %79.4779.9879.2378.8479.5579.0378.5678.0478.2378.7079.4978.30
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)366.4359.7335.7321.3373.7382.5402.5400.4446.0412.8464.6436.3
− Exceptional Items (reconciliation)0.00.00.00.00.0-73.60.00.00.0-48.20.00.0
Net Income Adj (tax-effected)276.7289.3251.5236.3281.8295.7319.0308.0491.3340.7342.2323.0
EPS Adj2.852.982.592.432.903.053.283.175.053.513.523.32
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital971.6971.8971.9971.9972.1972.1972.1972.2972.2972.8973.1973.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.